Miniatura

Fitxers

fimmu-13-918887.pdf (5.42 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2022-07-29

Llicència de publicació

cc by (c) Pernin, Vincent et al., 2022
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/188964

Impaired antigen-specific B-cell responses after Influenza vaccination in kidney transplant recipients receiving co-stimulation blockade with Belatacept

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.3389/fimmu.2022.918887

Resum

Emerging data suggest that costimulation blockade with belatacept effectively controls humoral alloimmune responses. However, whether this effect may be deleterious for protective anti-infectious immunity remains poorly understood. We performed a mechanistic exploratory study in 23 kidney transplant recipients receiving either the calcineurin-inhibitor tacrolimus (Tac, n=14) or belatacept (n=9) evaluating different cellular immune responses after influenza vaccination such as activated T follicular Helper (Tfh), plasmablasts and H1N1 hemagglutinin (HA)-specific memory B cells (HA(+)mBC) by flow-cytometry, and anti-influenza antibodies by hemagglutination inhibition test (HI), at baseline and days 10, 30 and 90 post-vaccination. The proportion of CD4+CD54RA-CXCR5+ Tfh was lower in belatacept than Tac patients at baseline (1.86%[1.25-3.03] vs 4.88%[2.40-8.27], p=0.01) and remained stable post-vaccination. At M3, HA(+)mBc were significantly higher in Tac-treated patients (0.56%[0.32-1.49] vs 0.27%[0.13-0.44], p=0.04) and correlated with activated Tfh numbers. When stratifying patients according to baseline HA(+)mBc frequencies, belatacept patients with low HA(+)mBC displayed significantly lower HA(+)mBc increases after vaccination than Tac patients (1.28[0.94-2.4] vs 2.54[1.73-5.70], p=0.04). Also, belatacept patients displayed significantly lower seroprotection rates against H1N1 at baseline than Tac-treated patients (44.4% vs 84.6%) as well as lower seroconversion rates at days 10, 30 and 90 after vaccination (50% vs 0%, 63.6% vs 0%, and 63.6% vs 0%, respectively). We show the efficacy of belatacept inhibiting T-dependent antigen-specific humoral immune responses, active immunization should be highly encouraged before starting belatacept therapy.

Matèries

Virus de la gripe, Trasplantament renal

Matèries (anglès)

Influenzavirus, Kidney transplantation

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

PERNIN, Vincent, MENEGHINI, Maria, TORIJA RECASENS, Alba, JOUVE, Thomas, DEL BELLO, Arnaud, SANZ MUÑOZ, Iván, EIROS, Jose maria, DONADEU, Laura, POLO, Carol, MORANDEIRA, Francisco, NAVARRO, Sergio, MASUET AUMATELL, Cristina, FAVÀ BUCH, Alexandre, LEQUINTREC, Moglie, KAMAR, Nassim, CRESPO, Elena, BESTARD MATAMOROS, Oriol. Impaired antigen-specific B-cell responses after Influenza vaccination in kidney transplant recipients receiving co-stimulation blockade with Belatacept. _Frontiers in Immunology_. 2022. Vol. 13. [consulta: 24 de gener de 2026]. ISSN: 1664-3224. [Disponible a: https://hdl.handle.net/2445/188964]

Exportar metadades

JSON - METS

Compartir registre